trastuzumab deruxtecan

25th Feb 2026

DESTINY-CRC02 trial results for trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary

This is a summary of the publication about the DESTINY-Gastric01 study, which was published in the New England Journal of Medicine in May 2020. The study included 187 adults in Japan and South Korea with gastric cancer or gastroesophageal junction cancer that had high levels of a protein called HER2 (HER2-positive). All the participants’ cancer had spread to nearby or distant parts of the body and had worsened after receiving at least 2 previous cancer treatments or treatment combinations. The researchers wanted to know whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants’ cancer more than standard chemotherapy drugs.

3rd Nov 2023

A plain language summary of the DESTINY-Gastric01 study: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer